{"schema_version":"secwatch.filing_event.v1","accession":"0001368148-23-000055","form_type":"8-K","ticker":null,"cik":"0001368148","company_name":"ATHERSYS, INC / NEW","filed_at":"2023-05-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.583696+00:00","generated_at":"2026-06-14T17:11:31.747258+00:00","sec_items":["1.01","2.03","2.02","3.02","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Athersys restructures $30.7M supplier debt; issues $15M convertible note at 10%","bullets":["Restructured $20.9M past-due and $9.8M future obligations under supplier agreements, less $3.9M in credits.","Pays $11.8M via monthly $250K cash payments starting Oct 2023; supplier forbears from remedies.","Issued $15M convertible note due May 2026, interest 10%, convertible at $1.30/share after 18 months.","Supplier granted exclusive option to supply 50% of material for MultiStem for 5 years after regulatory approval.","CEO Dan Camardo says restructuring reflects post-TREASURE trial needs and aligns with MASTERS-2 timeline after FDA Type B meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001368148-23-000055","json":"https://secwatch.observer/filing/0001368148-23-000055.json","markdown":"https://secwatch.observer/filing/0001368148-23-000055.md","text":"https://secwatch.observer/filing/0001368148-23-000055.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368148/000136814823000055/0001368148-23-000055-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368148/000136814823000055/athx-20230517.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T17:11:31.747258+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf7ae04e2bbfe312840c0092d3dc511039dca369","claim":"ATHERSYS, INC / NEW incurred convertible notes of $15.0 million with a supplier at 10.0% per annum maturing May 17, 2026.","evidence_excerpt":"the Company issued a convertible promissory note to the supplier in the principal amount of $15.0 million","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368148/000136814823000055/0001368148-23-000055-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$15.0 million"},{"label":"Counterparty","value":"a supplier"},{"label":"Rate","value":"10.0% per annum"},{"label":"Maturity","value":"May 17, 2026"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"5e4d3ce7f305e48eaee4be665cbba576c69bff6f","claim":"ATHERSYS, INC / NEW entered into new agreement with the supplier valued at $15 million convertible note.","evidence_excerpt":"Under the new agreement, Athersys will pay the supplier $11.8 million in monthly cash payments of $250,000 each, beginning October 2023. In addition, Athersys has issued a $15 million convertible note.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368148/000136814823000055/0001368148-23-000055-index.htm","confidence":0.4,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"the supplier"},{"label":"Value","value":"$15 million convertible note"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}